logo
Researchers link concerning factor to uptick in birth complications: 'Current regulations may be inadequate'

Researchers link concerning factor to uptick in birth complications: 'Current regulations may be inadequate'

Yahoo26-03-2025

Roundup is one of the most popular weedkillers in the United States, but the widespread use of the herbicide has created some troubling side effects.
As detailed by About Lawsuits, researchers Emmett Reynier and Edward Rubin from the University of Oregon conducted a study that determined that Roundup "may be responsible for a rise in birth complications among rural communities and historically disadvantaged groups."
Studies over the years have linked glyphosate, the active ingredient in Roundup, to an increased risk of adverse health effects despite previously being deemed safe for humans.
As part of their research, Reynier and Rubin found that the use of Roundup and other glyphosate-based herbicides increased astronomically by 750% in the U.S. since 1996. After that year, the duo "spotted a spike in the rates of low-weight births and preterm births in the areas where glyphosate was likely used," per About Lawsuits.
"Further, historically disadvantaged groups disproportionately bear these health effects," Reynier and Rubin wrote in the study. "These results conflict with current regulatory guidance, suggest current regulations may be inadequate, and highlight the need to improve pesticide use and exposure monitoring."
In addition to the potential side effects of Roundup exposure during pregnancy, the product has been found to cause an increased risk of non-Hodgkin's lymphoma. Public records show that over 120,000 lawsuits have been filed against Bayer and its Monsanto subsidiary, each of which raised similar allegations that users of Roundup developed non-Hodgkin's lymphoma when spraying the weedkiller in an agricultural setting or around their homes.
Bayer shelled out a whopping $10 billion-plus in Roundup settlements before announcing in 2021 that it planned to reformulate Roundup and remove the active ingredient glyphosate from consumer versions of the product. However, About Lawsuits pointed out that glyphosate "is still in the formulation for agricultural users," potentially exposing those who come in contact with the product to adverse health effects and increased risks of cancer.
In an update on March 5, Bayer announced that it is "investing and innovating to develop additional weed-control solutions." However, the company also brazenly stuck by its use of glyphosate, claiming, "For more than 50 years, leading health regulators around the world have repeatedly concluded that our glyphosate products can be used safely, and that glyphosate is not carcinogenic."
The simplest solution would be to stop buying glyphosate-based herbicides to address pesky weeds. However, people who live in rural areas still face possible exposure to the chemical due to its continued use for agricultural needs.
If you're in an area where you face potential exposure to glyphosate, some preventative measures include installing windbreaks, closing windows, reducing time outdoors during spray season, and cleaning regularly to remove household dust. Every possible step can help potentially protect maternal, fetal, and overall health.
Do you worry about pesticides in your food?
All the time
Sometimes
Not really
I only eat organic
Click your choice to see results and speak your mind.
Join our free newsletter for weekly updates on the latest innovations improving our lives and shaping our future, and don't miss this cool list of easy ways to help yourself while helping the planet.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

EMA says Ozempic, Wegovy may cause rare eye condition
EMA says Ozempic, Wegovy may cause rare eye condition

Yahoo

time17 hours ago

  • Yahoo

EMA says Ozempic, Wegovy may cause rare eye condition

-- The European Medicines Agency's (EMA) safety committee, PRAC, said Friday that it has concluded that Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION), a rare eye condition that can lead to vision loss, is a "very rare side effect" of semaglutide medicines, including Ozempic, Rybelsus, and Wegovy. The medications, owned by Novo Nordisk (NYSE:NVO), are widely used for the treatment of diabetes and obesity. Following a comprehensive review of all available data, including non-clinical studies, clinical trials, post-marketing surveillance, and medical literature, PRAC determined that NAION "may affect up to 1 in 10,000 people taking semaglutide." The firm explained that several large epidemiological studies indicate that adults with type 2 diabetes taking semaglutide face "an approximately two-fold increase in the risk of developing NAION" compared to those not on the medication. This is said to translate to about "one additional case of NAION per 10,000 person-years of treatment." The EMA added that clinical trial data also pointed to a "slightly higher risk" for those on semaglutide versus placebo. As a result, the EMA said it has recommended updating the product information for semaglutide medicines to include NAION as a "very rare" side effect. They conclude that patients experiencing "a sudden loss of vision or rapidly worsening eyesight" while on semaglutide are advised to contact their doctor immediately. If NAION is confirmed, "treatment with semaglutide should be stopped,' states the EMA. Related articles EMA says Ozempic, Wegovy may cause rare eye condition Virgin Galactic stock jumps on SpaceX competition speculation Vera Therapeutics stock sinks following competitor's successful trial

Cancer Risk at Air Force Missiles Sites Low 'But Not Zero,' Latest Service Data Shows
Cancer Risk at Air Force Missiles Sites Low 'But Not Zero,' Latest Service Data Shows

Yahoo

timea day ago

  • Yahoo

Cancer Risk at Air Force Missiles Sites Low 'But Not Zero,' Latest Service Data Shows

Airmen who watched over America's nuclear intercontinental ballistic missiles in Cold War-era facilities faced marginally higher risk of cancer due to contaminants found there and more workplace oversight is needed, according to the latest findings of an Air Force health study. Air Force Global Strike Command, during a town hall event Wednesday, released the latest data showing the slightly elevated cancer risk as part of its ongoing probe into health concerns for America's missileers, maintainers and other support roles at several bases in the Midwest and Western U.S. The lifetime cancer risk for all Americans is around 39%, and the Air Force's Health Risk Assessment found rates of 39.9% to 40.13% for men and women if they would have served anywhere from eight to 70 years in those jobs. Service officials said consistent workplace inspections and monitoring would likely be necessary to address the risks, which are caused by the presence of chemicals and toxins. Read Next: Army Faces Backlash over Plan to Divert Barracks Funds to Border Mission Contaminants linked to cancer were found during a series of environmental studies at F.E. Warren Air Force Base in Wyoming, Malmstrom Air Force Base in Montana, and Minot Air Force Base in North Dakota. "In summary, this health risk assessment characterizes the health risk as low but not zero," Col. Ric Speakman, the commander of the U.S. Air Force School of Aerospace Medicine, said during the town hall presentation. "Therefore, the appropriate action is to include missile alert facility workers in an occupational surveillance." Air Force Global Strike Command is still in the process of an ongoing epidemiological study and is gathering more data from states as well as national cancer registries before more definitive cancer and health conclusions can be made. Last year, reported in an investigative series that past probes by the Air Force into cancer concerns roughly two decades ago went ignored, and past and current missileers and nuclear missile maintainers raised alarms about the environmental conditions, toxins and chemical dangers they faced while in uniform. They believe the conditions made them sick. In the wake of reporting, the service announced changes that included new workplace inspections and health record tracking, and the spouse of a missileer who died from non-Hodgkin lymphoma was able to secure Department of Veterans Affairs benefits related to his death. While polychlorinated biphenyls, or PCBs, were one of the known outlawed carcinogenes that the Air Force's remediation efforts focused on, research shown during Wednesday's town hall showed there were other toxins detected as well that were factored into the service's health risk assessment. "Although only PCBs were detected at levels above the Environmental Protection Agency's standards for cleanup and remediation, the environmental sampling was sensitive enough to detect chemicals such as benzene and chloroform at levels well below standards for remediation," a Thursday news release from Air Force Global Strike Command following the town hall said. The Torchlight Initiative, a grassroots organization that began shortly after a Space Force officer and former Air Force missileer raised concerns about non-Hodgkin lymphoma rates at Malmstrom, released its own independent study in April examining the rates of blood cancer reported in its online health registry. That study found that service members were diagnosed at younger ages compared to the wider population. Air Force Global Strike Command officials briefly mentioned that study at the town hall, stating that, "while this study is separate from the missile community cancer study, it does add to the work advocacy and the well-being of the missile community." Representatives from the Torchlight Initiative were on Capitol Hill in early April alongside other advocacy groups, and made a plea to lawmakers in hopes of expanding the PACT Act -- a 2022 law that mostly covered veterans sickened by toxic exposure in war zones -- to cover those who experienced health issues stateside as well. "The Torchlight Initiative is happy to hear that Global Strike and U.S. Air Force School of Aerospace Medicine are still working on their long-term study and research," the organization said in a statement to on Thursday. "However, our focus and energy remains with the families who are disproportionately affected by these cancers and illnesses." The remaining data in the ongoing health study is slated to be released in late 2025. Gen. Thomas Bussiere, the head of Air Force Global Strike Command, said during the town hall he would advocate for a registry, if the VA also supported such a move, based on the study's findings. "The level of interest and oversight with the Department of the Air Force and Congress has not waned, and I'm very thankful and happy with the interest and actions on the part of the VA," Bussiere said in a news release after the town hall. "They've been great partners, and I anticipate they will continue to be great partners." Related: Independent Study Raises Alarm About Non-Hodgkin Lymphoma at Malmstrom Air Force Base

Bayer subsidiary Vividion secures rights to Werner helicase inhibitor
Bayer subsidiary Vividion secures rights to Werner helicase inhibitor

Yahoo

timea day ago

  • Yahoo

Bayer subsidiary Vividion secures rights to Werner helicase inhibitor

Bayer subsidiary Vividion Therapeutics has secured exclusive worldwide rights to develop and commercialise VVD-214, the Werner helicase (WRN) covalent inhibitor, enhancing its oncology pipeline. Roche and Vividion discovered and developed VVD-214 through a global partnership and licence agreement. In 2020, the companies agreed to discover and develop small molecules for a range of therapeutic targets. The acquisition of VVD-214 rights by Vividion complements its portfolio of investigational therapeutics aimed at treating cancers and immune disorders. Preliminary data from a Phase I trial indicated that the therapy is well-tolerated and exhibits signs of activity. The trial is assessing VVD-214 as a single agent and in conjunction with pembrolizumab for those with various solid tumours showing microsatellite instability (MSI), such as endometrial, colorectal, gastric and ovarian cancers. WRN is a deoxyribonucleic acid (DNA) repair enzyme and a synthetic lethal target for cancers with MSI. VVD-214's mechanism aims to induce lethal DNA damage in these cancers while sparing healthy cells. This approach could offer a new treatment avenue for patients with limited options, particularly those who relapse or become refractory to immune checkpoint inhibitors. Vividion Therapeutics CEO Aleksandra Rizo stated: 'Bringing VVD-214, the only clinical-stage covalent inhibitor of WRN in development worldwide, into our portfolio marks an incredibly exciting moment for Vividion. 'We are eager to progress development of this compound, building on the encouraging clinical data we've seen to date, as part of our mission to transform treatment for patients with cancer and other serious diseases.' Vividion has Phase I trials for other potential oral cancer therapies, including a Kelch-like ECH-associated protein 1 (KEAP1) activator, a RAS-phosphatidylinositol 3-kinase alpha (PI3Kα) inhibitor and a signal transducer and activator of transcription 3 (STAT3) inhibitor. The company is progressing the discovery of several drug programmes towards the clinic and has a pipeline of early discovery opportunities in immunology and oncology, utilising its chemoproteomics platform. "Bayer subsidiary Vividion secures rights to Werner helicase inhibitor" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store